Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2018
Pharmacy Choice - News - Drug Delivery Systems - October 20, 2018

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 87     Next >>     Go To Page:

10/20/18 - Topical Drug Delivery Market by Type (Hospital and Others) and Application (Hardware and Software): Growing at a CAGR of +7% from 2016 to 2022.: The Topical Drug Delivery Market Report includes a comprehensive analysis of the present market. The repo
New York, NY 10/19/2018 The Global Topical Drug Delivery Market is estimated at $89.76 billion in 2016 and is expected to reach $134.58 billion by 2022 growing at a CAGR of +7% from 2016 to 2022.. Topical drug delivery systems are designed to deliver drugs through topical routes such as the skin, mucosa or cavities in the body. Top Key Vendor
10/19/18 - Auto-Injectors Market Expected to Experience Immense Growth to Reach USD 2.4 Billion at 17.2% of CAGR During 20182022: The Medical Devices Market report titled Auto-Injectors Market Research Report- Global Forecast to 2022 is an expert analy
Pune, India 10/19/2018 Auto-Injectors is defined as a medical device which is designed to deliver a single dose of a life-saving drug. Auto injectors are easy to use and are intended for self administration by patients or can be administered by untrained personnel. The Global Auto-Injectors Market is expected to reach USD 2.4 billion by th
10/19/18 - ChemioCare Expands Proprietary Transdermal Platform
ChemioCare USA Inc., a biotech company focused on transforming patient outcomes in cancer supportive care, today announces a successful Drug Enforcement Administration registration: ChemioCare s exclusive formulation development partner, Transdermal Research Pharm Laboratories LLC, has obtained a new registration with the DEA as a Manufacturer
10/19/18 - CHMP issues a positive opinion for Bevespi Aerosphere for the treatment of chronic obstructive pulmonary disease
AstraZeneca today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for Bevespi Aerosphere in a pressurised metered-dose inhaler as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic..
10/19/18 - CHMP positive opinion Bevespi Aerosphere
AstraZeneca today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for Bevespi Aerosphere in a pressurised metered-dose inhaler as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic..
10/19/18 - Dual Chamber Injectors and Syringes Market to Garner Brimming Revenues by 2019
Albany, NY 10/19/2018 Dual chamber injectors and syringes are medical devices used to store active pharmaceutical components or biological substances that are not stable for extended period of time. These devices helps to maintain sterility of drugs before the time of injection in order to avoid drug loss.For example, liquid proteins drugs re
10/19/18 - Empower Clinics and Inolife R&D Announce Letter of Intent for US Distribution Agreement for Needle-free Treatments
Empower Clinics Inc., a leading owner and operator of medical cannabis and wellness clinics in the US, today announced that it has signed a letter of intent for a national distribution agreement with Inolife R&D, an emerging specialty medical device company. Under the agreement, Empower Clinics will make Inolife s pioneering needle-free injectio
10/19/18 - Global Medical Membrane Market: Key Insights Based on Product Type, End-Use and Regional Demand Till 2026: Medical membranes are used in drug delivery, bio-separation, and tissue regeneration as well as in diagnostic devices and artificial organs. Th
Albany, NY 10/18/2018 A fresh report has been added to the wide database of Market Research Report Search Engine. The research study is titled " Global Medical Membrane Market: key Insights Based on Product Type, End-use and Regional Demand Till 2026" which encloses important data about the production, consumption, revenue and market share, m
10/19/18 - Global Veterinary Vaccines markets, 2016-2024 - Spread of Zoonotic Diseases Propels Growth of Veterinary Vaccines
The "Veterinary Vaccines- Global Strategic Business Report" report has been added to ResearchAndMarkets.com' s offering. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Bayer AG Biogenesis Bago SA Boehringer Ingelheim International GmbH Ceva Sant Animale Elanco Animal Health Diamond Animal Health Indian..
10/19/18 - Inhalation Drug Delivery Devices Ingredient Market Top Manufacturers by 2025: 3M, Philips Healthcare, Novartis, GlaxoSmithKline: Our trend analysts at MarketExpertz look at Inhalation Drug Delivery Devices Ingredient Market for the crucial connection
The major players covered in this report are DeVilbiss Healthcare, 3 M Health Care, Hisamitsu Pharmaceutical, Teikoku Pharma, Philips Healthcare, Novartis, Smiths Medical, Allergan, Johnson& Johnson, Mylan, Teleflex Medical, CareFusion, DJO Global, Salter Labs, Monaghan Medical, GlaxoSmithKline. This report focuses on the top manufacturers in North
10/19/18 - Injectable Drug Delivery Devices Market Is Expected To Hold The Largest Industry Share By Growing At 11.8% Over The Projected Period 2018-2027
Injectable Drug Delivery Devices Market research report is exclusively published by Market Research Future to provide the overview of key players and their strategic profiles in the market and drawing a competitive landscape for the market along with detail information about drivers and factors restraining the market growth. Market Research Future.
10/19/18 - Medical Devices; Anesthesiology Devices; Classification of the Positive Airway Pressure Delivery System
Agency: " Food and Drug Administration, HHS." SUMMARY: The Food and Drug Administration is classifying the positive airway pressure delivery system into class II. FOR FURTHER INFORMATION CONTACT: Deepika Arora Lakhani, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 2543, Silver Spri
10/19/18 - Microneedle Drug Delivery Systems Market 2018-2025 Size, Share, Forecast and Analysis: The competitor research carried out accumulates information about both the existing as well as potential competitors operating in the global Microneedle Drug Deliv
New York, NY 10/18/2018 The latest research report on the Microneedle Drug Delivery Systems market for the forecast period, 2018- 2025 is involved in screening the business environment and the companies operating in the Microneedle Drug Delivery Systems industry. Importantly, the research sheds a lot of light on their winning strategies to he
10/19/18 - Opiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research
SANTA MONICA- Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that researchers at the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research and SUNY Upstate Medical University in Syracuse, NY, have been awarded a grant
10/19/18 - scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX
BURLINGTON- scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that, on October 16, 2018, it received minutes from the Type A Post-Action Meeting held on September
10/19/18 - scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX [Tehran Times (Iran)]
-scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced that, on October 16, 2018, it received minutes from the Type A Post-Action Meeting held on September 24, 2018 be
10/19/18 - ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
London- ViiV Healthcare today announced it has submitted a New Drug Application to the US Food and Drug Administration for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV-1 infection. Deborah Waterhouse, CEO, ViiV Healthcare, said,' We have now entered an exciting new era of treatments for people living wit
10/19/18 - Zydus Cadila gets USFDA nod for generic gout attacks drug [Tehran Times (Iran)]
Drug firm Zydus Cadila Thursday said it has received a tentative nod to market generic Colchicine tablets used for prevention and treatment of gout attacks in US market. The company has received the tentative approval from the United States Food and Drug Administration to market Colchicine tablets USP in the strength of 0.6 mg, Zydus Cadila said in
10/18/18 - A Study to Assess Bioquivalence Between a Novel Naproxen Sodium 275 mg Film-coated Tablet and Nalgesin Naproxen Sodium 275 mg Film-coated Tablet in Healthy Adult Volunteers
By a News Reporter-Staff News Editor at Mental Health Weekly Digest Staff editors report on the newly launched clinical trial, NCT03697889, which has the following summary description: "This is a research study designed to evaluate the rate and extent of absorption of Naproxen from a novel Naproxen sodium tablet and Nalgesin naproxen sodium 275 m
10/18/18 - An Open-lable, Single Arm, Single Center, Phase 2 Study of PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell
By a News Reporter-Staff News Editor at Cancer Vaccine Week Staff editors report on the newly launched clinical trial, NCT03701022, which has the following summary description: "This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refract
10/18/18 - BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea
By a News Reporter-Staff News Editor at Pharma Business Week BioPharmX Corporation, a specialty pharmaceutical company developing products for the dermatology market, announced that it has enrolled the first subject in a Phase 2 b clinical trial of BPX-04, a novel topical gel formulation of minocycline for the treatment of rosacea. The trial is a
10/18/18 - Breckenridge Announces Final Approval of its ANDA for Roflumilast Tablets Daliresp
By a News Reporter-Staff News Editor at Drug Week Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Roflumilast Tablets, 500 mcg, generic for Daliresp Tablets by AstraZeneca Pharmaceutical LP. Breckenridge's Roflumilast Tablets product
10/18/18 - Data on Drug Delivery Systems Discussed by Researchers at Department of Pharmaceuticals (Armamentarium of nanoscaled lipid drug delivery systems customized for oral administration: In silico docking patronage, absorption phenomenon, preclinical ...)
By a News Reporter-Staff News Editor at Biotech Week Researchers detail new data in Drugs and Therapies- Drug Delivery Systems. The news correspondents obtained a quote from the research from the Department of Pharmaceuticals, "In the past few years, we have find out that optimized composition of drug in lipid, surfactant, or mixture of lipid and
10/18/18 - Data on Nanogels Reported by Researchers at China Pharmaceutical University (Lipid-bilayer-coated nanogels allow for sustained release and enhanced internalization)
According to news originating from Jiangsu, People's Republic of China, by NewsRx correspondents, research stated, "Nanoparticle drug delivery system improves the therapeutic efficacy of a drug; however, achieving sustained release from nanoparticles is challenging, owing to the increase of surface area and pronounced burst release.
10/18/18 - FDA Approves Stiolto Respimat Supplemental New Drug Application sNDA to Add Data on COPD Exacerbation Reduction
By a News Reporter-Staff News Editor at Pharma Business Week Boehringer Ingelheim announced that the U.S. Food and Drug Administration approved new labeling for Stiolto Respimat Inhalation Spray that includes data showing a meaningful reduction in COPD exacerbations driven by tiotropium, which is the active ingredient in Spiriva Respimat Inhalati
Articles(s): 1 - 25 of 87     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415